Hepatitis B patients can take aspirin enteric-coated tablets and Rosuvastatin calcium tablets, but routine testing of liver function is required. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and anti-inflammatory effects, and the overall risk of clinically significant liver injury has been estimated to be only 1/100,000-8/100,000 patients on the drug, due to hepatocellular injury. Hepatotoxicity has been reported with most NSAIDs and is usually seen in the first 6-12 weeks of treatment and subsides within 4-8 weeks after discontinuation. Statins are commonly used to treat hypercholesterolemia and mixed hyperlipidemia. Adverse effects are less common with statins than with most other classes of lipid-lowering drugs. Adverse muscle events remain an important side effect of statins. Hepatic dysfunction is a concern, but the actual risk appears to be low. Clinical studies of statins have shown that the incidence of persistently elevated aminotransferase levels in patients treated with statins ranges from 0.5% to 3.0%. This occurs mainly during the first 3 months of treatment and is dose-dependent. If the patient’s alanine aminotransferase ALT level is confirmed to be elevated to more than 3 times the upper limit of normal by 2 tests, we recommend changing the drug or lowering the dose of the statin. Therefore, it is recommended to perform liver function tests before starting treatment with aspirin and statins, and thereafter routinely undergo monitoring of liver function and discontinue the drug in case of discomfort.